Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
Fund managers haven’t disclosed any holdings of KZR yet.
KZR Hedge Fund Activity: Q1 2026 in Review
43 of the 8,161 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2026, worth a combined $32.8M — up 17% from $28.1M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new KZR positions and 10 closed out — a net gain of 3 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Rangeley Capital, adding an estimated $1.02M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $1.74M sold.
- 43 institutional investors held Kezar Life Sciences (KZR) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $32.8M of Kezar Life Sciences stock for Q1 2026, up 17% quarter-over-quarter.
- 13 funds opened new Kezar Life Sciences positions in Q1 2026 and 10 closed out, a net change of +3 holders.
- The largest Kezar Life Sciences buyer in Q1 2026 was Rangeley Capital, an estimated $1.02M added.
- The largest Kezar Life Sciences seller in Q1 2026 was Nantahala Capital Management, an estimated $1.74M sold.
Based on aggregated 13F filings for Q1 2026.